A carregar...
Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
Advances in therapies have led to the approval of six therapeutic agents since 2004, each demonstrating overall survival benefit in randomized studies, and these have significantly improved the outlook for men facing metastatic castration-resistant prostate cancer (CRPC). More recently, efforts have...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5905496/ https://ncbi.nlm.nih.gov/pubmed/29695920 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S147168 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|